Argo Biopharma's siRNA Therapy Shows 99% HAE Attack Reduction in Phase II
Event summary
- Argo Biopharma to present Phase II updated results for BW-20805 at EAACI 2026 Congress (June 12-15, 2026).
- BW-20805 demonstrated 99% reduction in HAE attack rate in 600 mg Q24W group, with 83% attack-free.
- Plasma prekallikrein (PKK) reductions exceeded 90% across all groups, supporting Q6M dosing regimen.
- No drug-related severe adverse events reported; most common AE was mild, transient injection site reaction.
The big picture
Argo Biopharma's positive Phase II results for BW-20805 position it as a potential leader in long-acting HAE prophylaxis, addressing a critical unmet need in rare disease treatment. The data supports a shift toward less frequent dosing regimens, which could differentiate BW-20805 in a competitive landscape dominated by therapies requiring more frequent administration. The company's focus on RNAi therapeutics aligns with broader industry trends toward targeted, gene-silencing approaches for rare and specialty diseases.
What we're watching
- Regulatory Pathway
- Whether the sustained PKK suppression and safety profile will support accelerated regulatory review.
- Competitive Positioning
- How Argo Biopharma's long-acting prophylaxis compares to existing HAE treatments requiring frequent dosing.
- Pipeline Progression
- The pace at which Argo Biopharma advances BW-20805 into Phase III trials and expands its RNAi therapeutics pipeline.
Related topics